Literature DB >> 11752205

A novel class of peptides with facilitating action on neuronal nicotinic receptors of rat chromaffin cells in vitro: functional and molecular dynamics studies.

Silvia Di Angelantonio1, Valeria Costa, Paolo Carloni, Luigi Messori, Andrea Nistri.   

Abstract

Peptides related to the N-terminal region of calcitonin gene-related peptide (CGRP) were tested for their ability to modulate neuronal nicotinic acetylcholine receptors (nAChRs) of rat cultured chromaffin cells under whole cell patch-clamp conditions. Although CGRP(1-7) and CGRP(2-7) depressed responses mediated by nAChRs, CGRP(1-6), CGRP(1-5), or CGRP(1-4) rapidly and reversibly potentiated submaximal nicotine currents while sparing maximal currents. CGRP(1-3) was inactive. The threshold concentration for the enhancing effect of CGRP(1-6) was 0.1 microM. CGRP(1-5) or CGRP(1-4) were less effective than CGRP(1-6). Coapplication of CGRP(1-6) and of the allosteric potentiator physostigmine (0.5 microM) gave additive effects on nicotine currents. CGRP(1-6) did not enhance responses generated by muscle-type nicotinic receptors of cultured myoblasts or by gamma-aminobutyric acid(A) receptors expressed by human embryonic kidney cells. Molecular dynamics (MD) simulations suggested that CGRP(1-7) exhibited a relatively rigid ring structure imparted by the disulfide bridge between Cys(2) and Cys(7). The circular dichroism (CD) spectrum recorded from the same peptide was in agreement with this result. Shorter peptides, missing such a bridge, exhibited propensity for alpha-helix configuration. Replacing Cys(7) with Ala yielded CGRP(1-7A), a fragment with partial alpha-helix structure and ability to enhance nicotine currents. CD measurements on CGRP(1-6) were compatible with these MD structural findings. Short terminal fragments of CGRP represent a novel class of substances with selective, rapid, and reversible potentiation of nAChRs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752205     DOI: 10.1124/mol.61.1.43

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Prefrontal neuromodulation by nicotinic receptors for cognitive processes.

Authors:  Renata dos Santos Coura; Sylvie Granon
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

Review 2.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 3.  Acetylcholine nicotinic receptor subtypes in chromaffin cells.

Authors:  Manuel Criado
Journal:  Pflugers Arch       Date:  2017-08-08       Impact factor: 3.657

4.  Inhibition of native and recombinant nicotinic acetylcholine receptors by the myristoylated alanine-rich C kinase substrate peptide.

Authors:  Elaine A Gay; Rebecca C Klein; Mark A Melton; Perry J Blackshear; Jerrel L Yakel
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

5.  A structural model of agonist binding to the alpha3beta4 neuronal nicotinic receptor.

Authors:  Valeria Costa; Andrea Nistri; Andrea Cavalli; Paolo Carloni
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

Review 6.  Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells.

Authors:  Silvia Di Angelantonio; Rashid Giniatullin; Valeria Costa; Elena Sokolova; Andrea Nistri
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation.

Authors:  Rodrigo R Resende; Avishek Adhikari
Journal:  Cell Commun Signal       Date:  2009-08-27       Impact factor: 5.712

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.